Court of Appeal rules that a policy adopted by CCGs in north of England of offering bevacizumab (Avastin) for wet AMD is legal

The Court ruled unanimously that the policy, adopted by 12 CCGs, is lawful, with far-reaching implications for the NHS and drug industry. Arguments from Novartis and Bayer that the policy breached EU law on medicines and UK legislation were rejected.


British Medical Journal